Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P23760
UPID:
PAX3_HUMAN
Alternative names:
HuP2
Alternative UPACC:
P23760; G5E9C1; Q16448; Q494Z3; Q494Z4; Q53T90; Q6GSJ9; Q86UQ2; Q86UQ3
Background:
Paired box protein Pax-3, also known as HuP2, plays a pivotal role in neural development and myogenesis. It functions as a transcription factor, regulating cell proliferation, migration, and apoptosis. Pax-3 is a transcriptional activator of MITF, working synergistically with SOX10.
Therapeutic significance:
Pax-3 is implicated in several genetic disorders, including Waardenburg syndrome 1 and 3, Craniofacial-deafness-hand syndrome, and Rhabdomyosarcoma 2. These associations highlight its critical role in disease pathogenesis and underscore the potential of targeting Pax-3 in therapeutic strategies.